Navigation Links
DelMar Pharmaceuticals to Present Interim Clinical Data on VAL-083 in Refractory Glioblastoma at Society for Neuro-Oncology (SNO) Annual Meeting
Date:11/15/2012

armacokinetics and anti-tumor activity of VAL-083 in patients with histologically confirmed initial diagnosis of primary WHO Grade IV malignant glioma (GBM), now recurrent.  Patients with prior low-grade glioma or anaplastic glioma are eligible, if histologic assessment demonstrates transformation to GBM.  Patients with secondary brain tumors due to CNS metastases are also eligible for the study.

GBM patients must have been previously treated for GBM with surgery and/or radiation, if appropriate, and must have failed both Bevacizumab (Avastin®) and temozolomide (Temodar®), unless either or both are contra-indicated. 

Response to therapy and disease progression will be evaluated by MRI prior to each treatment cycle.  An initial phase of the study will involve dose escalation cohorts until a maximum tolerated dose (MTD) is established in the context of modern care.  Once the modernized dosing regimen has been established, additional patients will be enrolled at the MTD (or other selected optimum dosing regimen).

DelMar Pharma is conducting the study under the direction of Dr. Howard Burris at the Sarah Cannon Research Institute in Nashville, Tennessee with a second center in Sarasota, Florida. 

Please refer to clinicaltrials.gov identifier NCT01478178 for further details on this clinical trial.

About DelMar Pharma
Del Mar Pharmaceuticals was founded in 2010 to develop and commercialize proven cancer therapies in new orphan drug indications where patients are failing modern targeted or biologic treatments. The Company's lead asset, VAL-083, is currently undergoing clinical trials in the United States as a potential treatment for refractory glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer.  VAL-083 benefits from extensive clinical research sponsored by the US National Cancer Institute, and is currently approved for the treatment o
'/>"/>

SOURCE Del Mar Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Auspex Pharmaceuticals Receives U.S. Patent on Novel JAK Inhibitor SD-900
2. Access Pharmaceuticals To Host Third Quarter Investor Call on Wednesday, November 28th
3. Ground Zero Pharmaceuticals, Inc. (GZP) Announces Enhanced Biosimilars and Personalized Medicine Initiatives for its Clients
4. Cardioxyl Pharmaceuticals Raises $28 Million In Series B Financing Led By OrbiMed Advisors
5. Savara Pharmaceuticals AeroVanc Granted U.S. Orphan Drug Designation for the Treatment of MRSA Lung Infection in Cystic Fibrosis Patients
6. Edison Pharmaceuticals Announces Initiation of EPI-743 Phase 2B Leigh Syndrome Clinical Trial
7. Frost & Sullivan: Lack of Proper Price Regulation for Pharmaceuticals
8. Jazz Pharmaceuticals Announces Participation In Three Investor Conferences In November
9. Achillion Pharmaceuticals, Inc. Hosts the HCV Connection Media Briefing at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
10. Omthera Pharmaceuticals Presents Data From Analysis Of EVOLVE Trial Showing That Epanova Lowers ApoC-III, A Key Predictor of Cardiovascular Risk
11. Jazz Pharmaceuticals Announces Third Quarter 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)... 20, 2015 Research published today in the ... (PNAS) demonstrates that technology invented by researchers ... Eye Institute can improve the clinical management ... tomography (OCT) angiography could largely replace current dye-based ... OHSU researchers found that OCT angiography has ...
(Date:4/20/2015)... Ireland , April 20, 2015 ... that Charles M. Mayr , Chief Communications ... due to health reasons.  In conjunction with Mayr,s ... will assume the role of Chief Communications Officer, ... Kelly served as Senior Vice President, Chief Communications ...
(Date:4/20/2015)... Mass. , April 20, 2015 ... and final clinical results for the Phase 1 ... in HER2-positive metastatic breast cancer.  The results were ... clinical trials plenary oral session at the 2015 ... in Philadelphia, PA. Data ...
Breaking Medicine Technology:Study shows new technology may improve management of leading causes of blindness 2Study shows new technology may improve management of leading causes of blindness 3Study shows new technology may improve management of leading causes of blindness 4Study shows new technology may improve management of leading causes of blindness 5Actavis Announces Retirement of Charles M. Mayr 2Actavis Announces Retirement of Charles M. Mayr 3Merrimack Announces Final Clinical Results for MM-302 Phase 1 Study Demonstrating Robust Activity in Heavily Pre-Treated Patients with HER2-Positive Metastatic Breast Cancer 2Merrimack Announces Final Clinical Results for MM-302 Phase 1 Study Demonstrating Robust Activity in Heavily Pre-Treated Patients with HER2-Positive Metastatic Breast Cancer 3Merrimack Announces Final Clinical Results for MM-302 Phase 1 Study Demonstrating Robust Activity in Heavily Pre-Treated Patients with HER2-Positive Metastatic Breast Cancer 4Merrimack Announces Final Clinical Results for MM-302 Phase 1 Study Demonstrating Robust Activity in Heavily Pre-Treated Patients with HER2-Positive Metastatic Breast Cancer 5
... Zimmer Holdings, Inc. (NYSE and SIX: ZMH), a ... be participating in the 2011 Credit Suisse Annual Health ... in Phoenix, Arizona on November 9, 2011, at 8:00 ... of the presentation can be accessed via Zimmer,s Investor ...
... Leading academic and industry specialists to meet ... that could see R&D grind to a halt and the ... and screening the correct polymorphs and ensuring the characterisation of ... never been more vital. According to George Tranter from Chiralabs, ...
Cached Medicine Technology:Zimmer Holdings to Present at 2011 Credit Suisse Annual Health Care Conference 2Pharma Industry Unites With Academia to Tackle Ongoing Problem 2
(Date:4/20/2015)... The partners of Urgent Care of Westchester and ... Laser Med Spa with a special event. Residents of Westchester ... 12–7 p.m. on April 24 on 909 Midland Ave. in ... Participants will also get the chance to win free services ... any purchase, as well as up to 40 percent discounts ...
(Date:4/20/2015)... Tampa, Florida (PRWEB) April 20, 2015 ... Medicine’s Academy for Quality and Safety Improvement as the ... was presented at the association’s Annual Meeting, April 18, ... professionals work as a team, patient safety can be ... the association's president and CEO. “Northwestern Medicine and its ...
(Date:4/20/2015)... 2015 “Consumers deserve to know that their ... children’s hair will not put their health at risk,” said ... National Alliance for Hispanic Health, the nation’s leading Hispanic health ... not had authority to ensure cosmetic and personal care products ... had authority to get products off the shelves if they ...
(Date:4/20/2015)... April 20, 2015 The normal response from ... nothing more we could do.” Especially if the patient sought ... the response should be much different. So it’s critical the ... more can be done?” , Not every emergency room ... something that can be done.” But, according to Ronald ...
(Date:4/20/2015)... Florida Hospital at Connerton Long Term Acute ... Select Medical, during the annual ceremony hosted at the ... Operating Officer, Debi Martoccio, received the Leadership Award for ... six recipients out of 113 hospitals nationwide. The hospital ... the contributions to the community as well as a ...
Breaking Medicine News(10 mins):Health News:Bella Diosa Says Hello to Yonkers Community with Spa Party 2Health News:2015 Leape Ahead Award honors Northwestern Medicine’s Academy for Quality and Safety Improvement 2Health News:2015 Leape Ahead Award honors Northwestern Medicine’s Academy for Quality and Safety Improvement 3Health News:Statement of National Alliance for Hispanic Health on Senate Introduction of Personal Care Products Safety Act 2Health News:"What More Can Be Done?” – The Critical Question That Can Save a Stroke Victim 2Health News:"What More Can Be Done?” – The Critical Question That Can Save a Stroke Victim 3Health News:Florida Hospital at Connerton Long Term Acute Care Earns Awards from Select Medical including the Stu Dinney Humanitarian Award 2Health News:Florida Hospital at Connerton Long Term Acute Care Earns Awards from Select Medical including the Stu Dinney Humanitarian Award 3
... What: , The AACR 100th Annual Meeting will feature ... research. This year,s meeting focuses on innovative research, novel ... new approaches to cancer prevention. , To help you ... and related scientific abstracts will be available online at ...
... - Introducing the First and Only Non-Drowsy Allergy ... , KENILWORTH, N.J., Jan. 14 Schering-Plough ... the introduction of new CLARITIN(R) Liqui-Gels(R), the first ... liquid-filled capsule. Now available over-the-counter, CLARITIN(R) Liqui-Gels(R) provide ...
... 14 GLG Life Tech,Corporation (TSX: GLG) ("GLG" or ... including the growth of stevia plant leaf and high ... its 500 metric ton,(MT) high grade stevia processing line ... 97"). This line, located at the Company,s Qingdao,factory ...
... book-mark site,BETHESDA, Md., Jan. 14 The American Thoracic ... site -- www.cff.org -- the top online ... of the Web" review of 2008, the American Thoracic ... fibrosis. , , "This is an ...
... Coconut Scrub Added to Specialty Line for Tweens and ... offers girls of all ages clarifying products that are ... cause redness and irritation. The products include the Everyday ... all of which will be debuting at the New ...
... Accolate and Zyflo show no behavioral changes in ... continue , , WEDNESDAY, Jan. 14 (HealthDay News) -- An ... possible suicidal behavior among those taking asthma drugs has ... officials said Tuesday. , The FDA, which began the ...
Cached Medicine News:Health News:AACR 100th annual meeting 2009 2Health News:New Non-Drowsy CLARITIN(R) Liqui-Gels(R) Now Available 2Health News:New Non-Drowsy CLARITIN(R) Liqui-Gels(R) Now Available 3Health News:GLG Life Tech Corporation Announces Upgrade to 500 Metric Ton Processing Line for Increased Rebiana Output; Design Completed for Additional 2,000 Metric Tons 2Health News:GLG Life Tech Corporation Announces Upgrade to 500 Metric Ton Processing Line for Increased Rebiana Output; Design Completed for Additional 2,000 Metric Tons 3Health News:Cystic Fibrosis Foundation Web Site Rated 'Best of the Web' 2Health News:Glory for Girls Announces All-Natural Clarifying Products for Clear and Radiant Skin 2Health News:FDA Finds No Link So Far Between Asthma Drugs and Suicide Risk 2Health News:FDA Finds No Link So Far Between Asthma Drugs and Suicide Risk 3
Steerable catheter that is ideal for mapping unusual anatomy...
... The LASSO Circular Mapping Catheter from Biosense ... of circumferentially mapping the myocardial sleeves around ... allows the sequential assessment of PV potentials ... isolation. The circular LASSO curve with ...
Standard Deflectable Catheters...
... The reliable, easy-to-steer Bart EPXT ... shaft stability and curve control for ... point-of-tip actuation control supplies exceptional levels ... extraordinary family of small, medium and ...
Medicine Products: